Jubilant Ingrevia Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Stable quarter, bold ambition: Financial performance held steady QoQ despite a tough chemical cycle, while management unveiled Pinnacle 345, a 5-year roadmap targeting 3x revenue and 4x EBITDA.
• Volumes are returning, but pricing lags: Destocking appears largely over after 18 months, driving volume growth across segments, yet Chinese oversupply keeps pricing muted, compressing margins by 3–4 percentage points in Specialty Chemicals.
• The capex cycle is accelerating: ₹600–700 crores of the ₹2,000 crore modular plan will deploy in FY25, and management signaled an additional ₹1,500–2,000 crores will be needed beyond that to hit the 3x revenue target.
• CDMO is the growth engine, with new adjacencies: The pipeline is building on long-term contracts in agro and pharma, while early traction in semiconductor chemicals opens a new, high-growth vertical.
• What to watch next quarter: The conclusion of a large agrochemical intermediate contract, the pace of margin recovery as new plants ramp, and any firming of Chinese pricing, which management hopes to see in 1–2 quarters.

Pinnacle 345: The 5-Year Ambition

• The headline target: 3x revenue and 4x EBITDA over the next 5 years, a plan co-created by the entire leadership team in December and finalized with the board in February. A dedicated Program Management Office has been set up for rigorous tracking.
• The math to get there: The ₹2,000 crore modular capex plan plus existing business takes the top line to ~₹8,000 crores. To reach 3x from today's baseline, management estimates at least another ₹1,500–2,000 crores of capex, implying a run-rate of ₹500–600 crores annually from now onwards.
• Execution engine: Over 50 initiatives are running across business units and functions, each driven by a BU or functional head and directly championed by the CEO.
• Portfolio mix shift: Specialty Chemicals is expected to grow 3–3.5x in 3 years and become at least 60% of the overall business, with the bulk of growth coming from CDMO, fine chemicals (pyridine and diketene derivatives), and Microbial Solutions.
• Margin architecture: Steady-state margins are targeted north of 20% at the overall portfolio level, with Specialty Chemicals higher and Nutrition at least 15%+. Within Specialty, a richer mix of diketene derivatives, pyridine derivatives, agrochemical intermediates, and CDMO should push margins north of 20% in the next couple of years, up from 14–15% today.

Deepak Jain: "This is a bold vision and ambitious vision... that has been co-created by the whole leadership team of Jubilant Ingrevia, we created in December."

Demand & Pricing: A Two-Speed Recovery

• Volumes are healing, prices are not: After 18 months, destocking is at the far end and volumes are growing gradually across agrochemicals and pharma. However, Chinese oversupply continues to suppress prices, with agrochemical intermediates seeing 30–50% price declines.
• Segment-level pricing dynamics: Vitamin B3 pricing has been flat for 5–6 months, indicating stabilization but no uptick. In niacinamide, the animal sector faces more competition, while the human and food sector commands a price premium.
• The China plus one overhang: Inquiries from large companies for agrochemical intermediates are coming in, but buyers are deferring decisions because Chinese prices are too low. A large contract is expected to conclude in the coming quarter, but the broader strategy is on hold until Chinese pricing recovers.
• Pharma end-use is the bright spot: Demand from pharma continues to improve with a buoyant near-term outlook, though significant pricing recovery has yet to materialize. CDMO demand from North America and Europe grew during the quarter.
• Agrochemicals remain the laggard: The sector faced a dual challenge of inventory overstocking and Chinese oversupply. While excess inventory is expected to ease and volumes are likely to move, prices may remain under pressure, and the sector may take 1–2 more quarters to recover fully.

Shyam Bhartia: "The Agrochemicals sector, which faced dual challenge of overstocking of inventories and oversupply from China during the year, is yet to bounce back to normalcy, while the excess inventory situation is expected to ease out and volumes are likely to move, the prices may still remain under pressure due to excess supply of agrochemicals globally."

CDMO & New Verticals: Building the Pipeline

• CDMO is the core growth driver: High visibility exists on the future pipeline, with advanced-stage discussions to close long-term contracts across both agro and pharma sectors. The first CMO contractual order from the bigger agro intermediates plant shipped in February.
• Semiconductor chemicals: a new adjacency: Management previously had 3–4 leads; that has now grown to half a dozen, with most inquiries coming from international customers into the CDMO business. The focus is on making product to customer specifications, sending samples, and securing approvals for initial volumes, with hopes that volumes grow very fast given global semiconductor growth.
• Capital discipline on large contracts: Any specific large investment for CDMO will be made only on a take-or-pay basis, protecting the company from demand risk on dedicated assets.
• Microbial Control Solutions gaining momentum: New product launches in the Pyrithiones platform are expected to support accelerated growth going forward.

Shyam Bhartia: "Any large contract on CDMO and specific investments if we have to make, we'll be doing basically on the basis of take-or-pay. Otherwise, we will not be investing."

Capex & Capacity: Ramping the Engine

• FY25 capex deployment: ₹600–700 crores of the ₹2,000 crore modular plan remains to be spent, directed toward a food and cosmetic grade niacinamide plant (commissioning September), a food-grade choline (CC/CBT) plant, and expansion of GMP facilities. That number may increase once long-term contracts with large customers are signed.
• New plant ramp-up: Three plants commissioned in late FY24: a small agro intermediates plant (December), a bigger agro intermediates/access plant (January), and a diketene derivative plant (February–March). All are at 60%+ utilization and improving month-on-month.
• Diketene derivative traction: The new plant is already getting good traction, with capacity expected to fill in the next couple of quarters. Management is already thinking about debottlenecking and expansion, with Phase 3 and Phase 4 planned to capture a top-3 global position.
• Diketene Phase 2 ramp-up timeline: Expected to hit 70–80% utilization in the next 12 months, slightly delayed from normal 12–18 month curves due to the soft market environment.
• Derivative selection discipline: Management does not make all 30–40 possible diketene derivatives. It picks based on complexity, application, and margin profile, prioritizing only those with at least 20% EBITDA margins. Value addition per step varies significantly, and going too far out in the value chain can drop the margin profile if the intermediate is cheaply available from China.

Deepak Jain: "If there was value addition on every chemical, then we would have added like 50 derivatives by now, but that's not the case. So, you have to pick and choose based on several factors."

Segment Performance & Margins

• Specialty Chemicals: Volumes grew 30% QoQ, but continued pricing pressure kept EBITDA margins at 14–15%, a 3–4 percentage point erosion from the steady-state 17–18% in today's mix. The improvement in pharma demand and gradual agrochemical volume recovery are tailwinds, but Chinese oversupply remains the binding constraint.
• Nutrition & Health Solutions: Higher sales volumes from niacinamide were offset by muted pricing. Vitamin demand is stable, but competitive pressure persists across the product range. Customers are in buying mode but unwilling to accept higher pricing. Global market share in B3 increased in FY24, and food and cosmetics grade volumes registered significant growth sequentially and for the full year.
• Chemical Intermediates: Acetic Anhydride volumes were stable, but pricing was soft due to lower demand from paracetamol and agrochemical end-uses in both India and Europe, compounded by lower acetic acid raw material prices. The company maintained its dominant domestic market share and increased share in Europe.
• Margin headwinds: Higher freight costs from the Red Sea crisis dented overall margins, while continued lower utilization in downstream industries constrained volume pickup. Project Lean initiatives and focused inventory optimization brought working capital down to 18% of sales, providing some offset.
• Green chemistry advantage: The +99% Biogenic Content Rating for Green Acetic Acid is enabling a sales push with global food giants, creating a differentiated positioning in the intermediates segment.

Guidance & Commitments

Key Metrics